跳转至内容
Merck
  • Deep-brain stimulation associates with improved microvascular integrity in the subthalamic nucleus in Parkinson's disease.

Deep-brain stimulation associates with improved microvascular integrity in the subthalamic nucleus in Parkinson's disease.

Neurobiology of disease (2014-12-24)
Ilse S Pienaar, Cecilia Heyne Lee, Joanna L Elson, Louisa McGuinness, Stephen M Gentleman, Raj N Kalaria, David T Dexter
摘要

Deep brain stimulation (DBS) of the subthalamic nucleus (STN) has become an accepted treatment for motor symptoms in a subset of Parkinson's disease (PD) patients. The mechanisms why DBS is effective are incompletely understood, but previous studies show that DBS targeted in brain structures other than the STN may modify the microvasculature. However, this has not been studied in PD subjects who have received STN-DBS. Here we investigated the extent and nature of microvascular changes in post-mortem STN samples from STN-DBS PD patients, compared to aged controls and PD patients who had not been treated with STN-DBS. We used immunohistochemical and immunofluorescent methods to assess serial STN-containing brain sections from PD and STN-DBS PD cases, compared to similar age controls using specific antibodies to detect capillaries, an adherens junction and tight junction-associated proteins as well as activated microglia. Cellular features in stained sections were quantified by confocal fluorescence microscopy and stereological methods in conjunction with in vitro imaging tools. We found significant upregulation of microvessel endothelial cell thickness, length and density but lowered activated microglia density and striking upregulation of all analysed adherens junction and tight junction-associated proteins in STN-DBS PD patients compared to non-DBS PD patients and controls. Moreover, in STN-DBS PD samples, expression of an angiogenic factor, vascular endothelial growth factor (VEGF), was significantly upregulated compared to the other groups. Our findings suggest that overexpressed VEGF and downregulation of inflammatory processes may be critical mechanisms underlying the DBS-induced microvascular changes.

材料
货号
品牌
产品描述

Sigma-Aldrich
过氧化氢 溶液, contains inhibitor, 30 wt. % in H2O, ACS reagent
Sigma-Aldrich
过氧化氢 溶液, 30 % (w/w) in H2O, contains stabilizer
Sigma-Aldrich
过氧化氢 溶液, 50 wt. % in H2O, stabilized
Sigma-Aldrich
N-羟基丁二酰亚胺, 98%
Sigma-Aldrich
邻二甲苯, puriss. p.a., ≥99.0% (GC)
Sigma-Aldrich
邻二甲苯, reagent grade, ≥98.0%
Sigma-Aldrich
过氧化氢溶液, 30% (w/w), puriss. p.a., reag. ISO, reag. Ph. Eur.
Sigma-Aldrich
过氧化氢 溶液, contains ~200 ppm acetanilide as stabilizer, 3 wt. % in H2O
Sigma-Aldrich
过氧化氢 溶液, contains inhibitor, 35 wt. % in H2O
Sigma-Aldrich
过氧化氢 溶液, purum p.a., ≥35% (RT)
Sigma-Aldrich
3,3′-二氨基联苯胺, 97%
Millipore
过氧化氢 溶液, 3%, suitable for microbiology
Supelco
过氧化氢 溶液, ≥30%, for trace analysis
Supelco
邻二甲苯, suitable for HPLC, 98%
Sigma-Aldrich
过氧化氢 溶液, contains inhibitor, 30 wt. % in H2O, meets USP testing specifications
Supelco
柠檬酸钠, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
过氧化氢 溶液, 34.5-36.5%
Supelco
过氧化氢 溶液, 30 % (w/w), for ultratrace analysis
Sigma-Aldrich
邻二甲苯, anhydrous, 97%
Sigma-Aldrich
3,3′-二氨基联苯胺, 97% (HPLC)
Sigma-Aldrich
过氧化氢 溶液, SAJ first grade, ≥30.0%
Supelco
邻二甲苯, analytical standard
Sigma-Aldrich
柠檬酸 三钠盐, ≥98% (GC), anhydrous
Sigma-Aldrich
三(叔丁氧基)硅烷醇, 99.999%
Sigma-Aldrich
柠檬酸盐浓缩液, BioReagent, suitable for coagulation assays, 4 % (w/v)
Sigma-Aldrich
柠檬酸盐浓缩液, BioUltra, for molecular biology, 1 M in H2O
Sigma-Aldrich
过氧化氢 溶液, tested according to Ph. Eur.
Sigma-Aldrich
N-羟基丁二酰亚胺, purum, ≥97.0% (T)
Supelco
邻二甲苯, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
抗-VE-钙粘蛋白抗体(CD144),克隆BV9, clone BV9, from mouse